Marksans Pharma (MARKSANS.BO) Earnings Analysis

Marksans Pharma (MARKSANS.BO) next reports earnings on 2026-08-06, consensus EPS 3.3 INR. It has beaten estimates in 1/1 recent quarters (100%). Trailing P/E 26.75.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does MARKSANS.BO next report earnings?

Next earnings date2026-08-06
Consensus EPS estimate3.3 INR
Revenue estimate8.50B

MARKSANS.BO earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-263.25 INRn/an/an/a
2026-02-052.5 INR2.4 INR+4.2%Beat
2025-11-132.2 INRn/an/an/a
2025-05-192 INRn/an/an/a

Beat rate: 1/1 (100%) over reported quarters with consensus data.

MARKSANS.BO valuation and analyst view

Trailing P/E26.75
Trailing EPS9.225 INR
Price / book3.70
Dividend yield0.32%
Market cap108.93B

Limited or no published sell-side analyst coverage for this symbol.

Related research pages

Frequently asked questions

When is Marksans Pharma (MARKSANS.BO)'s next earnings date?

Marksans Pharma is next scheduled to report on 2026-08-06, with a consensus EPS estimate of 3.3 INR and revenue estimate of 8.50B.

Did MARKSANS.BO beat earnings last quarter?

Consensus estimate data was not available for MARKSANS.BO's 2026-05-26 report.

What is MARKSANS.BO's earnings track record?

Over the last 1 reported quarters with consensus data, MARKSANS.BO beat estimates 1 times (100%).

What is MARKSANS.BO's current P/E ratio and EPS?

MARKSANS.BO trades at a trailing P/E of 26.75 on trailing EPS of 9.225243601460505 INR.

What do analysts rate MARKSANS.BO?

MARKSANS.BO has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.